{"id":390678,"date":"2018-05-17T00:00:00","date_gmt":"2018-05-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0043-2018-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-pediatric-us-2018\/"},"modified":"2026-04-17T05:29:04","modified_gmt":"2026-04-17T05:29:04","slug":"algoim0043-2018-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-pediatric-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0043-2018-biopharma-ulcerative-colitis-treatment-algorithms-claims-data-analysis-pediatric-us-2018\/","title":{"rendered":"Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2018"},"content":{"rendered":"<p>The primary goal of ulcerative colitis (<abbr title=\"ulcerative colitis\">UC<\/abbr>) treatment is to induce and maintain remission with few to no clinical symptoms remaining. Conventional therapies (5-<abbr title=\"aminosalicylate\">ASA<\/abbr>s, corticosteroids) are typically used to treat mild to moderate <abbr title=\"ulcerative colitis\">UC<\/abbr>, whereas intravenous and subcutaneous tumor necrosis factor-alpha (<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1) inhibitors are primarily reserved for moderate to severe disease refractory to conventional treatment or for first-line treatment of the most-severe disease. Takeda\u2019s Entyvio, a cell adhesion molecule (<abbr title=\"cell adhesion molecule\">CAM<\/abbr>) inhibitor approved for adult <abbr title=\"ulcerative colitis\">UC<\/abbr>, offers an alternative treatment option, especially for <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1-refractory patients; however, it is not approved for pediatric <abbr title=\"ulcerative colitis\">UC<\/abbr>. Still, given the limited treatment options for pediatric <abbr title=\"ulcerative colitis\">UC<\/abbr> patients who fail <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors, physicians may turn to Entyvio for some patients. Indeed, the availability of newer agents will likely make the treatment landscape more complex.<\/p>\n<p><strong>QUESTIONS ANSWERED:<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed pediatric <abbr title=\"ulcerative colitis\">UC<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric <abbr title=\"ulcerative colitis\">UC<\/abbr> patients?<\/li>\n<li>What proportion of pediatric <abbr title=\"ulcerative colitis\">UC<\/abbr> patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of pediatric <abbr title=\"ulcerative colitis\">UC<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated pediatric patients with <abbr title=\"ulcerative colitis\">UC<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION: <\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em> provides detailed analysis of brand usage across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.<\/p>\n<p><strong>Geographies: <\/strong>United States<\/p>\n<p><strong>Real-world data: <\/strong>Longitudinal patient-level claims data analysis<\/p>\n<p><strong>Key drugs covered: <\/strong> Remicade, Humira, Simponi, Entyvio, oral\/rectal aminosalicylates, immunosuppressants<\/p>\n<p><strong>Key analysis provided: <\/strong><\/p>\n<ul>\n<li>Brand useacross longitudinal patient sample.<\/li>\n<li>Newly diagnosed patient analysis.<\/li>\n<li>Treatment initiation and progression.<\/li>\n<li>Line of therapy analysis.<\/li>\n<li>Combination therapy analysis.<\/li>\n<li>Source of business for recently treated patients.<\/li>\n<li>Persistency and compliance analysis.<\/li>\n<li>Product-level patient flowcharts.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390678","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ulcerative-colitis","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390678\/revisions"}],"predecessor-version":[{"id":393802,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390678\/revisions\/393802"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}